drugset
drugset / Trial / NCT01736241

A Study of LY3053102 in Healthy Participants

NCT01736241 ↗

Phase 1 Completed 41 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study was to evaluate the safety and tolerability of the study drug known as LY3053102 in healthy participants. The study also investigated how much of the study drug entered the blood stream and how long it took the body to dispose of the study drug. Information about any side effects that occurred was also collected. The study was expected to last approximately 8 weeks for each participant (up to 4 weeks from screening to the administration of study drug and an additional 4 weeks of follow up).

Timeline

Start
2012-12
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3053102 Unknown 2 mg Subcutaneous
Subject LY3053102 Unknown 7 mg Subcutaneous
Subject LY3053102 Unknown 20 mg Subcutaneous
Subject LY3053102 Unknown 50 mg Subcutaneous
Subject LY3053102 Unknown 150 mg Subcutaneous
Subject LY3053102 Unknown 405 mg Subcutaneous

Indications

No indication recorded.